Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus

BACKGROUND: The relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated. METHODS: Per protocol, at baseline all SLE subjects enrolled in this longitudinal study p...

Descripción completa

Detalles Bibliográficos
Autores principales: Buyon, Jill, Furie, Richard, Putterman, Chaim, Ramsey-Goldman, Rosalind, Kalunian, Kenneth, Barken, Derren, Conklin, John, Dervieux, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Biomarker Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051407/
https://www.ncbi.nlm.nih.gov/pubmed/27752336
http://dx.doi.org/10.1136/lupus-2016-000165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051407/
https://www.ncbi.nlm.nih.gov/pubmed/27752336
http://dx.doi.org/10.1136/lupus-2016-000165

Ejemplares similares